Alumis Inc. Common Stock (ALMS) Research

Alumis Inc. is a biopharmaceutical firm currently in the clinical trial phase, dedicated to advancing and marketing therapeutic solutions for a range of autoimmune conditions. Its pipeline includes ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor, which is being investigated for its potential in addressing plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis. Another key candidate is A-005, also an allosteric TYK2 inhibitor, specifically designed to penetrate the central nervous system to target neuroinflammatory and neurodegenerative disorders. Originally established as Esker Therapeutics, Inc., the organization rebranded as Alumis Inc. in January 2022. Founded in 2021, Alumis maintains its corporate headquarters in South San Francisco, California.

Market snapshot

Symbol
ALMS
Price
$23.41
Day change
+1.56%
Market cap
$2.9B
P/E ratio
-12.33x
52-week range
2.76-30.6
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$39.33

Peer companies

  • ADC Therapeutics S.A. (ADCT)
  • Bicycle Therapeutics plc (BCYC)
  • Eton Pharmaceuticals, Inc. (ETON)
  • Fulcrum Therapeutics, Inc. (FULC)
  • Lineage Cell Therapeutics, Inc. (LCTX)
  • Lexicon Pharmaceuticals, Inc. (LXRX)
  • Neumora Therapeutics, Inc. Common Stock (NMRA)
  • Ocugen, Inc. (OCGN)

Recent insider activity

  • Drappa Jorn — M-Exempt (15535 shares) on 2026-05-22
  • Drappa Jorn — M-Exempt (11317 shares) on 2026-05-22
  • Drappa Jorn — M-Exempt (15535 shares) on 2026-05-22
  • Drappa Jorn — M-Exempt (11317 shares) on 2026-05-22
  • Foresite Labs, LLC — J-Other (1123337 shares) on 2026-04-01

Open Alumis Inc. Common Stock (ALMS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.